ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

OMTH Omthera Pharmaceuticals, Inc. (MM)

13.30
0.00 (0.00%)
Last Updated: 00:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
Omthera Pharmaceuticals, Inc. (MM) NASDAQ:OMTH NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 13.30 0 00:00:00

OMTHERA PHARMACEUTICALS SHAREHOLDER ALERT: Levi & Korsinsky Notifies Investors of Claims of Breaches of Fiduciary Duty by Board

04/06/2013 10:12pm

GlobeNewswire Inc.


OMTHERA PHARMACEUTICALS, INC. (NASDAQ:OMTH)
Historical Stock Chart


From Jan 2020 to Jan 2025

Click Here for more OMTHERA PHARMACEUTICALS, INC. Charts.

Levi & Korsinsky notifies investors of Omthera Pharmaceuticals, Inc. ("Omthera" or the "Company") (Nasdaq:OMTH) of claims of breaches of fiduciary duty and other violations of state law against the board of directors of the Company in connection with the sale of the Company to AstraZeneca Plc (NYSE:AZN). A complaint was filed in Delaware state court.

Click here to learn more about the investigation http://zlk.9nl.com/omthera-pharamaceuticals-omth/, or call: 877-363-5972. There is no cost or obligation to you.

Under the terms of the transaction, Omthera shareholders will receive $12.70 for each share of Omthera stock they own. In addition, Omthera shareholders will receive approximately $4.70 in contingent value rights if certain benchmarks are met. Including the contingent rights, the transaction has a total approximate value of $443 million. The claims concern whether the Omthera Board of Directors breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into the transaction, whether AstraZeneca is underpaying for Omthera stock, thus unlawfully harming Omthera shareholders.

If you own common stock in Omthera and wish to obtain additional information, please contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/omthera-pharamaceuticals-omth/.

Levi & Korsinsky is a national firm with offices in New York, New Jersey and Washington D.C. The firm has extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. The attorneys at Levi & Korsinsky have been appointed by numerous courts throughout the country to serve as lead counsel on behalf of shareholders in major securities lawsuits and have successfully recovered multimillion-dollar damages awards on behalf of investors. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT: Levi & Korsinsky, LLP
         Joseph Levi, Esq.
         Eduard Korsinsky, Esq.
         30 Broad Street - 24th Floor
         New York, NY 10004
         Tel: (212) 363-7500
         Toll Free:  (877) 363-5972
         Fax: (212) 363-7171
         www.zlk.com

1 Year OMTHERA PHARMACEUTICALS, INC. Chart

1 Year OMTHERA PHARMACEUTICALS, INC. Chart

1 Month OMTHERA PHARMACEUTICALS, INC. Chart

1 Month OMTHERA PHARMACEUTICALS, INC. Chart

Your Recent History

Delayed Upgrade Clock